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The development of inhibitors of microbial attachment to target cells has been proposed recently as a possible novel 
approach to antimicrobial chemoprophylaxis and treatment. In this paper an attempt is made to contend that such artifi- 
cial inhibitors must be polyvalent, i.e. capable of binding to the pathogen or its target by multiple bonds. 
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1. INTRODUCTION 
The initial step in any viral infection is the at- 
tachment of the virus to specific cellular receptors 
which is mediated by viral attachment proteins 
(VAPs). This step may determine, in many cases, 
the outcome of virus-cell encounters, host range 
and tissue tropism of the virus [l-5]. The possibili- 
ty has been shown of virus neutralization by block- 
ing the receptor-binding epitopes of VAPs with 
soluble cellular receptors or their synthetic 
analogs, for example, cellular membrane lipid 
fractions for rabies virus [6,7], synthetic sialosides 
for myxoviruses [8], recombinant soluble forms of 
CD4 antigen [9,10] or synthetic peptide fragment 
of CD-4 [l l] for human immunodeficiency 
viruses. 
Most natural bacterial infections are also in- 
itiated by adhesion of microorganisms to the 
mucosal surfaces of the host. The attachment pro- 
teins of bacteria (the so-called adhesins) interact 
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usually with carbohydrate determinants of host 
cell glycolipids or glycoproteins [ 12-141. In a 
number of experiments the attachment of 
microorganisms to target cells in vitro was com- 
pletely prevented and infected animals were pro- 
tected by competitive blocking of microbial 
adhesins with specific sugars, oligosaccharides or 
glycoproteins [ 1% 191. 
It has been postulated that the process of tumor 
metastasis into certain organs is similar to that of 
infection of target tissues by bacteria: organotropy 
of both infectious diseases and metastasis can be 
mediated by lectins of either the invaded organs or 
of the invading bacteria or tumor cells [20]. 
Repeated administration of the hepatic lectin- 
blocking agents D-galactose or arabinogalactan 
prevented metastatic dissemination into the liver of 
mice of experimental sarcoma and lymphoma [21]. 
These facts support the plausibility of a recently 
proposed novel approach to the prophylaxis and, 
possibly, early treatment of microbial infections 
and tumor metastasis based on the development of 
drugs which inhibit pathogen attachment o host 
cells [2,6,12,20-221. The potential benefits of this 
approach are blocking of the first stage of infec- 
Published by Etsevier Science Publishers B. V. (Biomedical Division) 
00145793/89/$3.50 0 1989 Federation of European Biochemical Societies 1 
Volume 252, number 1,2 FEBS LETTERS July 1989 
tion preceding pathogen multiplication, probable 
low toxicity of the drug to the host and its wide 
range of action as many serotypes, types and even 
unrelated species of viruses and bacteria are known 
to recognise the same receptors on the target cells 
[l-5,12,13]. Although in principle two alternative 
modes of intervention into pathogen-cell interac- 
tion are possible, i.e. blocking of (i) either active 
epitopes of the pathogen’s attachment proteins, or 
(ii) receptors for pathogen on cells, the latter mode 
[21,22] seems less promising in terms of potential 
ability to violate the normal physiology of the host 
cells. In either case, however, in order to develop 
potent inhibitors of attachment of microorganisms 
to cells, suitable for medical applications, it is 
obligatory to consider the multi-bond cooperative 
character of microbial reception. 
2. COOPERATIVE NATURE OF MICROBIAL 
RECEPTION NECESSITATES THE 
POLYVALENCY OF INHIBITORS 
All viruses, bacteria and cells are polyvalent, i.e. 
they contain multiple copies of attachment pro- 
teins on their surface (up to a few hundred for 
viruses, and even more for bacteria and cells), and 
thus can attach to their targets, which are also 
polyvalent, by multiple bonds. It is calculated that 
many viruses, when binding to cells, interact with 
not less than 10 monomeric cellular receptor 
molecules (the so-called cellular receptor units - 
CRUs), being organized into polyvalent ‘cellular 
receptor sites’ (CRS) [ 11. The characteristic feature 
of such polyvalent cooperative binding is that the 
high avidity of binding may be mediated by multi- 
ple low-affinity individual contacts [ 1,23,24]. For 
example, the apparent binding constants of 
isolated spike glycoproteins of Semliki forest virus, 
in the form of water-soluble octameric complexes, 
to cells was shown to be lOO-lOOO-fold lower than 
that determined for the whole virus containing ap- 
prox. 260 spikes 1251. 
Concerning the design of drugs which block 
microbial attachment o target cells and consider- 
ing the cooperative nature of this attachment, it 
was suggested [6,26] that the traditional phar- 
macological approach - designing of low 
molecular mass competitive inhibitors of the cor- 
responding active epitope - would not work in this 
case, as monovalent compounds would not be able 
2 
to compete effectively with the polyvalent interac- 
tion of a microorganism with the cell. Analysis of 
data in the literature and presented below substan- 
tiates this conclusion. 
Thus, it is well known that mucoproteins in- 
terfere with hemagglutination by myxoviruses as a 
result of blocking of their attachment proteins with 
mucoprotein’s sialic acid residues, the minimum 
active determinants, recognised on a host cell sur- 
face by many viruses. Orosomucoid, a serum 
glycoprotein containing N-acetylneuraminic acid 
(NeuAc), does not inhibit hemagglutination, ow- 
ing to its molecular mass being too low [27]. It was 
found that incubation of orosomucoid at 80°C 
caused its polymerization and conversion to a po- 
tent inhibitor of hemagglutination by influenza 
viruses [28]. This shows that an increase in 
molecular mass, and hence in valency of the in- 
hibitor, augments its activity. 
In order to investigate the detailed specificity of 
the influenza virus hemagglutinin receptor-binding 
epitope, the ability of some natural and synthetic 
monovalent sialosides to inhibit adsorption of the 
virus on human erythrocytes was compared [29]. 
The inhibition was dose-dependent with a steep 
slope for the inhibition curve reflecting the highly 
cooperative nature of the virus-erythrocyte interac- 
tion. About 7 mM (4.4 mg/ml) sialyllactose was 
required for 50% inhibition of binding, and 
15 mM for complete inhibition. Although some 
sialosides were more potent inhibitors than 
sialyllactose, it seems doubtful that monovalent 
sialosides can be found which will be sufficiently 
active for practical use as anti-influenza drugs. The 
same is true for known monovalent inhibitors of 
bacterial adhesion, which must be used at very 
high concentrations (up to 5 mg/ml) to prevent in- 
fection completely [17,18]. Recently, high 
molecular mass sialylglycoprotein inhibitors of in- 
fluenza virus hemagglutination, low pH-fusion 
and hemolysis were synthesized starting with the 
so-called glycoprotein 2 (GP2) from bovine 
erythrocyte membranes [30]. These artificial 
sialylglycoproteins contained about 200 NeuAc 
groups bound per 250 kDa GP2 macromolecule 
and inhibited hemagglutination by influenza 
viruses at concentrations of 1.2-4.5 pg/ml 
(l-4,uM with respect to NeuAc), i.e. they were 
lOOO-times more potent inhibitors than the above- 
mentioned monovalent sialosides 1291. 
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Similar conclusions about the superiority of 
polyvalent inhibitors can be drawn from a study 
[3 l] in which the nature of the cellular receptors on 
swine nasal mucosa for Bordetelia bronchiseptica 
bacteria, pathogenic to this animal, has been in- 
vestigated. Among the different mono- and 
oligosaccharides and glycoproteins tested, only 
those containing NeuAc inhibited the adhesion of 
bacteria to target cells in vitro, thus confirming the 
involvement of sialic acid residues exposed on 
cellular surfaces. The polyvalent NeuAc- 
containing inhibitors - bovine submaxillary mucin 
and gangliosides (the latter form multimeric 
micelles in solution) - were effective even at 
0.075 mg/ml @O-97% inhibition of adhesion), 
which is lOO-times lower than the concentration of 
monovalent NeuAc and sialyllactose needed to 
prevent binding by only 55 and 66%, respectively. 
The species-specific reaggregation of cells of the 
marine sponge Microciona prolifera cells is 
mediated by ‘sticky’ proteoglycan aggregation fac- 
tor (MAF) having a molecular mass of about 
20 MDa and consisting of more than 1300 copies 
of the monovalent glycopeptide fragment T-10 
(10 kDa) [32]. The apparent binding affinity to 
sponge cells of individual T-10 molecules is com- 
paratively low, i.e. 3 x lo6 M which is 13000-times 
lower than that of native MAF. As a result, the 
ability of T-10 to inhibit MAF binding to sponge 
cells is also low: as much as 320 pg unlabeled T-10 
was needed for 50% inhibition of adsorption to 
cells in competitive assays using 0.29 /cg 1251-MAF. 
T-10 can be polymerized by cross-linking with 
glutaraldehyde; the binding to cells and inhibitory 
activity of the resulting T-10 polymers increased 
proportionally with their size. Only 0.51 rg of 
15 MDa T-10 polymer (about 1500 copies of T-10) 
was needed for 50% inhibition of 0.29pg 12’1- 
MAF adsorption [32]. 
Just as for viruses, bacteria and other cor- 
puscular organisms polyvalency and cooperativity 
of attachment o cellular receptors necessitate the 
polyvalent structure of inhibitors of adsorption for 
some biopolymers [33,34]. For example, shiga tox- 
in from ShigeZZa dysenteriae type 1 specifically 
binds to cellular glycoproteins or glycolipids hav- 
ing the galabiose disaccharide (Gabl-4Gal@) as a 
common determinant [34]. The monomeric disac- 
charide did not inhibit the toxin binding to HeLa 
cells in monolayers. However, the binding and 
cytotoxicity of the toxin were inhibited by 
galabiose covalently linked to BSA. Increasing the 
number of galabiose residues coupled per BSA 
molecule from 7 to 25 reduces the concentration of 
inhibitor required for 50% inhibition from 100 to 
1 pg/ml. 
All the examples listed show that multimeric 
polyvalent inhibitors of attachment of viruses, 
bacteria, cells, toxins and some other biopolymers 
are several orders of magnitude more active than 
the analogous monovalent compounds. Further- 
more, by polymerising a weak inhibitor (i.e. in- 
creasing its valency) a very potent agent can be 
obtained. 
It may be stated therefore that the development 
of artificial inhibitors of microbial attachment 
must include as a necessary step the designing of 
such a form of the inhibitor that will provide 
multi-site polyvalent binding to the target, i.e. 
pathogen or its receptor on susceptible cells. 
To produce such polyvalent structures, one 
might utilize some principles of the design of the 
well-known ‘drug delivery systems’, for example, 
coupling the monovalent inhibitory active 
molecules in multiple copies to soluble biocompati- 
ble polymers or microparticulate carriers - 
liposome, synthetic microcapsule, micelle ,
polymeric, proteinaceous, carbohydrate or lipid 
nanoparticle, etc. The contemporary state of the 
field of drug delivery provides an abundant spec- 
trum of methods and materials that can be used for 
the production of polyvalent inhibitors - potential 
drugs for clinical application (reviews [35-371). 
Besides the already mentioned advantage of 
enhanced activity of drugs solely due to 
cooperativity of binding to the target, the propos- 
ed approach to the design of inhibitors of 
microbial adhesion may have other possible 
benefits. Firstly, large polyvalent macromolecular 
or corpuscular inhibitors would be able to 
neutralise pathogens not only by competitive in- 
hibition of receptor-binding sites of adhesins, 
which demands a manyfold excess of inhibitor, but 
also by steric hindrance of pathogen attachment, 
endocytosis, fusion with cellular memhrane, un- 
coating, etc. Secondly, by choosing the ap- 
propriate carrier or including supplementary 
functional components in the composition of the 
‘inhibitor delivery system’, one can influence the 
mode of interaction of inhibitor with its target 
3 
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and, as a result, bring about an additional increase 
in its neutralizing potency. Finally, utilization of 
polyvalent instead of monovalent inhibitors 
reduces the likelihood of non-neutralizable 
mutants appearing, since the possible lowering of 
the avidity of individual contacts as a result of a 
mutation in the receptor-binding site of the 
microorganism would be compensated to some ex- 
tent by the cooperativity of binding. 
The correctness of and the prospects for the 
practical use of this approach to the design of an- 
timicrobial agents could be evaluated in the future 
by using a model of those pathogens for which the 
structure of cellular receptor determinants or 
receptor-binding epitopes of the pathogen are 
known, for example influenza virus [26], human 
immunodeficiency virus [ 1 I], some bacteria 
[12-141 and tumors [21]. 
3. CONCLUSION 
The idea of inhibition of a pathogen’s attach- 
ment to host cells by suitably designed drugs may 
help to create a novel approach to prophylaxis and 
treatment of infectious diseases. In this paper, 
selected data on inhibition of attachment of 
viruses, bacteria, cells and microbial toxins have 
been reviewed and discussed, leading to the conclu- 
sion that such drugs must be polyvalent, i.e. 
capable of multi-site cooperative binding to the 
pathogen or its receptors on susceptible cells. 
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